Clinuvel Pharmaceuticals logo

CUV - Clinuvel Pharmaceuticals Share Price

A$29.7 0.3  0.9%

Last Trade - 7:10am

Mid Cap
Market Cap £809.0m
Enterprise Value £769.2m
Revenue £21.8m
Position in Universe 248th / 1896
Unlock CUV Revenue
Relative Strength (%)
1m +13.1%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -3.79%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
3.67 7.03 17.0 25.8 31.6 33.1 44.9 54.4 +55.3%
+85.2 +37.1 -10.2 +10.6 -5.79
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ClinuvelPharmaceuticals Limited revenues increased 55% to A$16M.Net income increased from A$611K to A$6.5M. Revenuesreflect Commercial sales of goods increase of 84% toA$13.6M. Net income benefited from Total expenses decreaseof 91% to A$63K (expense), Business Marketing & Listingdecrease of 18% to A$727K (expense), Research & DevelopmentExpense decrease of 11% to A$986K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CUV
Graphical History


CUV Revenue Unlock CUV Revenue

Net Income

CUV Net Income Unlock CUV Revenue

Normalised EPS

CUV Normalised EPS Unlock CUV Revenue

PE Ratio Range

CUV PE Ratio Range Unlock CUV Revenue

Dividend Yield Range

CUV Dividend Yield Range Unlock CUV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CUV EPS Forecasts Unlock CUV Revenue
Profile Summary

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company. The Company is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. It is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for patients with vitiligo. Its pipeline includes research and development into a pediatric formulation of SCENESSE; SCENESSE for adult vitiligo patients; SCENESSE for adult patients with VP; products based on melanocortin analogues CUV9900 and Parvysmelanotide (VLRX001) and a range of over the counter products for general photoprotective application.

Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated December 14, 1999
Public Since February 13, 2001
No. of Shareholders: 5,438
No. of Employees: 16
Sector Healthcare
Industry Pharmaceuticals
Index S&P/ASX All Ordinaries , S&P/ASX 200 , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 49,410,338
Free Float (0.0%)
Eligible for
CUV Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CUV
Upcoming Events for CUV
Frequently Asked Questions for Clinuvel Pharmaceuticals
What is the Clinuvel Pharmaceuticals share price?

As of 7:10am, shares in Clinuvel Pharmaceuticals are trading at A$29.7, giving the company a market capitalisation of £809.0m. This share price information is delayed by 15 minutes.

How has the Clinuvel Pharmaceuticals share price performed this year?

Shares in Clinuvel Pharmaceuticals are currently trading at A$29.7 and the price has moved by 47.25% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Clinuvel Pharmaceuticals price has moved by 12.96% over the past year.

What are the analyst and broker recommendations for Clinuvel Pharmaceuticals?

Of the analysts with advisory recommendations for Clinuvel Pharmaceuticals, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Clinuvel Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Clinuvel Pharmaceuticals next release its financial results?

Clinuvel Pharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Clinuvel Pharmaceuticals dividend yield?

The Clinuvel Pharmaceuticals dividend yield is 0.08% based on the trailing twelve month period.

Does Clinuvel Pharmaceuticals pay a dividend?

Last year, Clinuvel Pharmaceuticals paid a total dividend of 0.03, and it currently has a trailing dividend yield of 0.08%. Looking ahead, Clinuvel Pharmaceuticals has not announced an ex-dividend date yet.

When does Clinuvel Pharmaceuticals next pay dividends?

Clinuvel Pharmaceuticals has yet to annouce their ex-dividend date. The historic dividend yield on Clinuvel Pharmaceuticals shares is currently 0.08%.

How do I buy Clinuvel Pharmaceuticals shares?

To buy shares in Clinuvel Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Clinuvel Pharmaceuticals?

Shares in Clinuvel Pharmaceuticals are currently trading at A$29.7, giving the company a market capitalisation of £809.0m.

Where are Clinuvel Pharmaceuticals shares listed? Where are Clinuvel Pharmaceuticals shares listed?

Here are the trading details for Clinuvel Pharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: CUV
What kind of share is Clinuvel Pharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Clinuvel Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Clinuvel Pharmaceuticals share price forecast 2021?

Shares in Clinuvel Pharmaceuticals are currently priced at A$29.7. At that level they are trading at 3.62% premium to the analyst consensus target price of 0.00.

Analysts covering Clinuvel Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of 0.363 for the next financial year.

How can I tell whether the Clinuvel Pharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Clinuvel Pharmaceuticals. Over the past six months, the relative strength of its shares against the market has been 11.26%. At the current price of A$29.7, shares in Clinuvel Pharmaceuticals are trading at 29.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Clinuvel Pharmaceuticals PE Ratio?

The Clinuvel Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 68.76. The shares are currently trading at A$29.7.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals's management team is headed by:

Philippe Wolgen - CEO
Dennis Wright - CSO
Darren Keamy - CFO
Brenda Shanahan - NID
Willem Blijdorp - NEC
Karen Agersborg - NED
Susan Smith - NED
Jeffrey Rosenfeld - NED
Who are the major shareholders of Clinuvel Pharmaceuticals?

Here are the top five shareholders of Clinuvel Pharmaceuticals based on the size of their shareholding:

ACN 108 768 896 Pty. Ltd. Corporation
Percentage owned: 5.93% (2.93m shares)
Ender 1, L.L.C. Corporation
Percentage owned: 5.24% (2.59m shares)
Blijdorp (Willem) Individual Investor
Percentage owned: 3.53% (1.74m shares)
Wolgen (Philippe Jacques) Individual Investor
Percentage owned: 2.64% (1.30m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 2.03% (1.00m shares)
Similar to CUV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.